GABA channels and dopamine in striatum
纹状体中的 GABA 通道和多巴胺
基本信息
- 批准号:8244526
- 负责人:
- 金额:$ 37.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-03-01 至 2015-02-28
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAnimal ModelBehaviorCellsCorpus striatum structureCyclic AMP-Dependent Protein KinasesDataDiseaseDopamineDopamine AgonistsDopamine D2 ReceptorDopamine ReceptorDrug AddictionElectrophysiology (science)EquilibriumFunctional disorderGABA ReceptorGilles de la Tourette syndromeGlutamatesGreen Fluorescent ProteinsHealthHuntington DiseaseInterneuronsKnockout MiceLabelLocomotionMediatingMembraneMental HealthMental disordersModelingMotor ActivityMotor outputMouse StrainsMovementMovement DisordersMusMuscimolNeuronsNeurosciencesOutputParkinson DiseasePathway interactionsPeptidesPharmaceutical PreparationsPharmacologyPhosphoric Monoester HydrolasesPhosphorylationPhosphotransferasesPhysiologicalPlayPopulationPotassium ChannelPropertyProtein KinaseReceptor ActivationRecombinantsRelative (related person)ReportingRoleSliceSubstantia nigra structureTardive DyskinesiaTestingThalamic structureTransgenic MiceWhole-Cell RecordingsWild Type MouseWorkbasecomparativegamma-Aminobutyric Acidmotor learningnerve supplynervous system disorderneuropeptide Ynew therapeutic targetpatch clampreceptorreceptor expressionreceptor functionred fluorescent proteinresearch studyselective expressiontraffickingtransmission process
项目摘要
DESCRIPTION (provided by applicant): The striatum controls the execution of learned motor behaviors as well as the suppression of unwanted movements. The main neuronal type in the striatum, the medium spiny neuron (MSN), receives converging glutamatergic innervation from the cortex and thalamus and dopaminergic innervation from the substantia nigra. In addition a small population of GABAergic interneurons controls the excitability of a vast population of MSNs to maintain the proper balance of information outflow for smooth control of motor output. This control is exerted via both phasic and tonic GABAa receptor activation. This project aims to compare GABA receptor-mediated currents and the receptor subtypes amongst MSNs originating the striatopallidal and the striatonigral pathways. We will utilize corticostriatal slices made from strains of mice which selectively express green or red fluorescent protein in D1 or D2 dopamine receptor expressing cells to identify unique properties of GABAa receptors in these cells. Single cell electrophysiology in corticostriatal slices will be used to test the hypothesis that that a portion of striatal GABAa receptors have unique properties and are unequally distributed between the two major subtypes of striatal projection neurons. Based on preliminary data showing that striatopallidal MSN express a tonic conductance mediated by a subtype of GABAa channel, the first specific aim will strive to understand the role of alpha and beta subunits of GABAa receptors in producing this tonic activation in MSNs. This will be done with subunit selective drugs, mice lacking specific subunits and recombinant GABA channels relevant to striatal MSNs. The second aims will test the hypothesis that protein kinase phosphorylation regulates the functional properties of tonically active GABA channels. The last aim will investigate if the presence of the specific and distinct dopamine receptors in MSN subtypes plays a role in setting the properties and regulating the expression of GABA receptor subtypes that can be target for pharmacological therapy of disorders associated with striatal dysfunction.
PUBLIC HEALTH RELEVANCE: Striatopallidal and striatonigral medium spiny neurons are the major output neurons from the mammalian striatum, control movements and become imbalanced in movement disorders. Previous reports have suggested that dopamine depletion induces changes in GABA receptors which exacerbate this imbalance of striatal output. Additionally, the systemic administration of the GABAA receptor agonist muscimol, increased locomotor activity in dopamine receptor D2 knockout mice, a model of Parkinson's disease while reducing locomotion in wild type mice. Using transgenic mice with the two major striatal output pathways labeled, we will have a unique opportunity to answer a fundamental question: What role tonic and phasic GABA conductance plays in striatal disorders? As GABAa receptor have a quite established pharmacology, the proposed study has great potential to identify novel therapeutic targets for treating disorders associated with striatal dysfunction including Parkinson's disease, Huntington's disease, tardive dyskinesia, Tourette's syndrome and drug addiction. In addition, as the pharmacology of two major classes of DA receptors has such critical role in mental illness, the results we will derive, although clearly related to basic neuroscience, will have notable applications to both neurological disorders and to mental health.
描述(由申请人提供):纹状体控制学习的运动行为的执行以及对不想要的运动的抑制。纹状体中的主要神经元类型,即中型多刺神经元(MSN),接受来自皮质和丘脑的会聚性多巴胺能神经支配和来自黑质的多巴胺能神经支配。此外,少量GABA能中间神经元控制大量MSN的兴奋性,以维持信息流出的适当平衡,从而平稳控制运动输出。这种控制通过阶段性和紧张性GABA α受体激活来实现。本项目旨在比较GABA受体介导的电流和受体亚型之间的MSN起源的纹状体和纹状体黑质途径。我们将利用由在D1或D2多巴胺受体表达细胞中选择性表达绿色或红色荧光蛋白的小鼠品系制成的皮质纹状体切片来鉴定这些细胞中GABA α受体的独特性质。皮质纹状体切片中的单细胞电生理学将用于检验以下假设:纹状体GABA a受体的一部分具有独特的性质,并且在纹状体投射神经元的两种主要亚型之间不均匀分布。基于初步数据显示,纹状体的MSN表达由GABA α通道的亚型介导的紧张性传导,第一个具体的目标将努力了解GABA α受体的α和β亚基在MSN中产生这种紧张性激活的作用。这将与亚基选择性药物,小鼠缺乏特定的亚基和重组GABA通道相关的纹状体MSN。第二个目标将测试的假设,蛋白激酶磷酸化调节紧张活性GABA通道的功能特性。最后一个目的将调查MSN亚型中特异性和独特的多巴胺受体的存在是否在设置特性和调节GABA受体亚型的表达中起作用,所述GABA受体亚型可以是与纹状体功能障碍相关的疾病的药理学治疗的靶点。
公共卫生相关性:纹状体苍白球和纹状体黑质中棘神经元是哺乳动物纹状体的主要输出神经元,控制运动并在运动障碍中变得不平衡。先前的报告表明,多巴胺耗竭诱导GABA受体的变化,这加剧了纹状体输出的不平衡。此外,全身施用GABAA受体激动剂蝇蕈醇增加了多巴胺受体D2敲除小鼠(帕金森病模型)的运动活性,同时减少了野生型小鼠的运动。使用两个主要的纹状体输出通路标记的转基因小鼠,我们将有一个独特的机会来回答一个基本的问题:什么样的作用紧张和相位GABA电导纹状体疾病?由于GABA α受体具有相当成熟的药理学,因此所提出的研究具有很大的潜力来确定用于治疗与纹状体功能障碍相关的疾病的新的治疗靶点,所述疾病包括帕金森病、亨廷顿病、迟发性运动障碍、图雷特综合征和药物成瘾。此外,由于两大类DA受体的药理学在精神疾病中具有如此重要的作用,我们将得出的结果尽管与基础神经科学明显相关,但对神经系统疾病和精神健康都有显着的应用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stefano Vicini其他文献
Stefano Vicini的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stefano Vicini', 18)}}的其他基金
GABAergic Interneurons Regulate Brainstem Neural Circuitry
GABA能中间神经元调节脑干神经回路
- 批准号:
9927621 - 财政年份:2018
- 资助金额:
$ 37.46万 - 项目类别:
GABAergic Interneurons Regulate Brainstem Neural Circuitry
GABA能中间神经元调节脑干神经回路
- 批准号:
10163174 - 财政年份:2018
- 资助金额:
$ 37.46万 - 项目类别:
GABAergic Interneurons Regulate Brainstem Neural Circuitry
GABA能中间神经元调节脑干神经回路
- 批准号:
9594647 - 财政年份:2018
- 资助金额:
$ 37.46万 - 项目类别:
GABAergic Interneurons Regulate Brainstem Neural Circuitry
GABA能中间神经元调节脑干神经回路
- 批准号:
9757771 - 财政年份:2018
- 资助金额:
$ 37.46万 - 项目类别:
Cerebellar Inhibitory Synapses in GABAR subunits KO mice
GABAR 亚基 KO 小鼠的小脑抑制性突触
- 批准号:
6856589 - 财政年份:2003
- 资助金额:
$ 37.46万 - 项目类别:
Cerebellar Inhibitory Synapses in GABAR subunits KO mice
GABAR 亚基 KO 小鼠的小脑抑制性突触
- 批准号:
6606572 - 财政年份:2003
- 资助金额:
$ 37.46万 - 项目类别:
Cerebellar Inhibitory Synapses in GABAR subunits KO mice
GABAR 亚基 KO 小鼠的小脑抑制性突触
- 批准号:
6700776 - 财政年份:2003
- 资助金额:
$ 37.46万 - 项目类别:
Cerebellar Inhibitory Synapses in GABAR subunits KO mice
GABAR 亚基 KO 小鼠的小脑抑制性突触
- 批准号:
7195005 - 财政年份:2003
- 资助金额:
$ 37.46万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 37.46万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 37.46万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 37.46万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 37.46万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 37.46万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 37.46万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 37.46万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 37.46万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 37.46万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 37.46万 - 项目类别:
Grant-in-Aid for Scientific Research (C)